[Comunicado de imprensa – ainda não publicado] Em análise final, pílula da Pfizer contra Covid mantém a eficácia de 89% em reduzir o risco de internação ou morte.

Comunicado de imprensa: Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel Covid-19 oral antiviral treatment candidate in reducing risk of hospitalization or death

Comentários:

Pfizer’s Covid pill remains 89% effective in final analysis, company says – STAT

Pfizer confirms COVID pill’s results, potency versus omicron – Associated Press

Conteúdos relacionados:

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

Comentário no Twitter (fio – clique para saber mais)

@pfizer releases more nirmatrelvir (#Paxlovid) data on #COVID19 final outcomes. Data are consistent, slightly better thant interim analysis. #IDTwitter
▪️ 88% overall hospitalization <=5days
▪️ No deaths in High Risk Trial (EPIC-HR)
▪️ Stopping drug 2.1%https://t.co/1D2LKan7tM

— David Boulware, MD MPH (@boulware_dr) December 14, 2021